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Introduction: Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of
Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the
preferred epitope or conformation of amyloid-β to target for treatment, and the mechanism of action underlying
immunotherapy. Bapineuzumab (humanized 3D6), a neo-epitope specific antibody recognizing amyloid-β1-5 with
strong preference for an exposed Asp residue at the N-terminus of the peptide, has undergone advanced clinical
testing for treatment of AD.
Methods: To gain further insight into the epitope conformation, we interrogated structural details of amino-terminal
epitopes in amyloid-β using x-ray crystallography of 3D6Fab:amyloid-β complexes. Humanization of 3D6 was carried
out using standard procedures integrating recombinant methods, sequence informatics, and homology modeling
predictions to identify important mouse framework residues for retention in the finished humanized product.
Results: Here we report the crystal structure of a recombinant Fab fragment of 3D6 in complex with amyloid-β1-7
solved at 2.0 Å resolution. The N-terminus of amyloid-β is bound to 3D6 as a 310 helix. The amino-terminal Asp residue
is buried deepest in the antibody binding pocket, with the Cβ atom of residue 6 visible at the entrance to the binding
pocket near the surface of the antibody. We further evaluate homology model based predictions used to guide
humanization of 3D6 to bapineuzumab, with actual structure of the Fab. The structure of the Fab:amyloid-β complex
validates design of the humanized antibody, and confirms the amyloid-β epitope recognized by 3D6 as previously
mapped by ELISA.
Conclusions: The conformation of amyloid-β antigen recognized by 3D6 is novel and distinct from other antibodies
recognizing N-terminal epitopes. Our result provides the first report demonstrating structural conservation of antigen
contact residues, and conformation of antigen recognized, between the parent murine antibody and its humanized
version.Introduction
Immunotherapy targeting amyloid beta (Aβ) peptide has
been demonstrated to prevent or reverse a range of Alz-
heimer’s disease (AD) related pathologies, in both trans-
genic mouse models and AD patients [1-5]. Efficacy
against Aβ related behavioral deficits has also been re-
ported in transgenic mouse models of AD [6-9]. Despite
the failure of initial efforts with immunotherapy to meet* Correspondence: gur1balbasi@gmail.com
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stated.primary endpoints in pivotal clinical trials [10,11], the pre-
ponderance of successful pre-clinical studies targeting Aβ
provide support for ongoing clinical trials with Aβ im-
munotherapy for treatment of AD in humans, evidenced
by the multiplicity of approaches continuing clinical test-
ing [12-15] (ClinicalTrials.gov Identifier: NCT01760005).
A number of important questions regarding efficacy
following Aβ immunotherapy remain under investiga-
tion. These include: 1) the mechanisms of action; 2) pre-
ferred Aβ epitope to target; and 3) the specific form of
Aβ recognized by a given antibody. In our hands, anti-
body isotypes with maximal effector function targetingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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across a number of end-points in preclinical studies
[5,16,17]. Fine mapping the epitope specificity among
antibody responders from an active vaccination phase 2
trial in AD patients immunized with AN1792 (Aβ1-42
peptide) revealed exquisite specificity for the amino-
terminus of Aβ peptide [18], providing some clinical
support for targeting the amino-terminus of Aβ for AD
immunotherapy.
Among the efficacious in vivo amino-terminal epitope
targeting antibodies we characterized and humanized for
clinical development, the antibody 3D6 presented an at-
tractive candidate due to its neo-epitope specificity for
the amino-terminus of Aβ, namely a strong preference
for a free Asp residue at position 1 of Aβ. This unique
specificity of 3D6 precludes recognition of unprocessed
amyloid precursor protein (APP) (hypothesized to be a
desirable attribute in a clinical candidate), and is pre-
served in bapineuzumab (humanized 3D6, version 2), as
reported below. Furthermore, the 3D6 epitope is detect-
able in all forms of Aβ tested [5], from compacted β-
amyloid plaques in AD and platelet-derived growth fac-
tor (PDGF) promoter driven APP transgenic mouse
model of AD (PDAPP) brain, to soluble oligomeric spe-
cies. The latter are thought to be a primary mediator of
neurotoxicity, and have also been postulated to underlie
behavioral impairments in AD Tg mice [19]. In sum-
mary, the properties of 3D6 most closely reflected the
antibody response mapped in AN1792 treated AD pa-
tients [18], supporting advancement of bapineuzumab
(humanized 3D6v2) for clinical development [3,20-22].
To gain further insight into this specific Aβ epitope
for immunotherapy of AD, we investigated antigen con-
formation recognized by different antibodies targeting
amino-terminal epitopes of Aβ using X-ray crystallog-
raphy of antibody:Aβ co-complexes solved to very high
resolution (1.5 to 3 Å for all antibodies) [23]. Previously,
we reported that three independently derived antibodies
targeting Aβ residues 3–7 recognize antigen in an ex-
tended conformation along the surface of the antibody
binding site [23]. Here we report that, in contrast, anti-
body 3D6, targeting Aβ residues 1–5, binds antigen in a
310 helix. The antigen is bound by antibody such that
the amino-terminus of the peptide is buried in a cleft in
the antibody binding site, and the carboxy-terminus
winds out to the surface of the antibody. Taken together,
our findings reveal distinct conformations adopted by the
amino-terminal epitope of Aβ, consistent with independ-
ent reports from other groups [24-26], and offer a testable
hypothesis for the combinatorial manipulation of antibody
activities targeting Aβ, for example, as bi-specific anti-
bodies (wherein each arm of the Fab recognizes a different
epitope/conformation of Aβ), incorporating the appropri-
ate Fc isotype (for desired effector functions).The high resolution crystal of 3D6 Fab + Aβ reported
here, coupled with the structure of 4HIX (an early ver-
sion of humanized 3D6 containing mouse framework
residues deemed dispensable in bapineuzumab, see Re-
sults) in complex with Aβ [24] afforded the opportunity
for retrospectively evaluating the humanization design of
3D6 leading to bapineuzumab. Comparison of our struc-
ture with 4HIX illustrates conservation of antigen con-
formation, and all features of antigen recognition by the
antibody. This comparative analysis validates the design
of bapineuzumab and attests to the robustness of anti-
body humanization technology as a platform for obtain-
ing clinical development candidates from preclinical
leads for disease therapy in humans.
Methods
Crystallization
Recombinant 3D6 Fab was expressed and purified from
mammalian cell culture supernatant as previously de-
scribed [23]. Crystallization conditions are summarized
in Additional file 1: Table S1. Crystals of 3D6 Fab with
either Aβ1-7 peptide or Aβ1-40 peptide were grown at
22 °C and frozen in liquid nitrogen for data collection.
Data collection
Diffraction data for 3D6Aβ1-7 and 3D6Aβ1-40 were
measured at 100 K at beamline 12–2 of the Stanford
Synchrotron Radiation Lightsource. Data were processed
with MOSFLM and SCALA [27]. Data statistics are
summarized in Table 1.
Structure determination
Molecular replacement calculations were performed
using the program COMO [28]. Molecular replacement
was done in two stages, first finding the rotation and
translation solution of the constant domain and later,
while fixing the constant domain, finding the solution
for the variable domain. Model building was done using
the program Coot [29]. The structures were initially re-
fined using Refmac [27] and at later stages using Phenix
[30] with individual positional and B-factor refinement
and five Translation Libration Screw (TLS) groups (the
heavy and light chains were split into two groups each,
at the hinge between the constant and the variable do-
mains, and the peptide as a separate group).
In the final model of 3D6 + Aβ1-7 the side chain of
residue 6 was not visible past Cβ. Only Aβ residues 1–5
are visible in the 3D6 + Aβ1-40 crystal structure. These
crystals were grown in the 200 mM Zn2+, and several
strong difference electron density peaks were modeled
as Zn2+, based on the geometry of the surrounding li-
gands and the appearance of strong peaks at these posi-
tions in an anomalous difference map. One of these Zn2+
ions occupies the same spatial position as Aβ1-40 and
Table 1 Crystallographic data statistics
3D6Aβ1-7 3D6Aβ1-40
Space group C2 P2221
Unit cell lengths (Å) a = 126.8 a = 40.0
angles (°) b = 69.4 b = 84.9
c = 61.7 c = 175.9
β = 115.4
Resolution Å(last shell) 2.0 (2.05) 2.2 (2.26)
Rsym(last shell)
a 6.5 (23.0) 5.9 (18.9)
Mean((I)/σ(I)) 15.0 (5.0) 19.9 (7.9)
% completeness (last shell) 100 (100) 100 (100)
Average multiplicity 3.8 (3.7) 5.8 (5.9)
Residues in final model (total) 1-218 (219) 1-204,
Light chain 1–132, 207–216 (219)







Average B (Å2) 28.5 29.4
Bond length RMSD (Å) 0.007 0.008
Angle RMSD (°) 1.1 1.2
Ramachandran plot: (% in preferred/
allowed/ outliers regions)b
97.2/2.8/0.0 95.8/3.9/0.3
aRsym = ∑ h ∑ I(| Ii(h) − < I(h) > |) /∑h ∑ iIi(h) where Ii(h) = observed intensity, and
< I(h) > = mean intensity obtained from multiple measurements. R and Rfree = ∑
h|Fo(h) − Fc(h)| /∑hFo(h), where Fo(h) = observed structure factor amplitude and
Fc(h) = calculated structure factor amplitude for the working and test sets,
respectively. bAs defined in Coot. RMSD, root mean square deviation of
atomic position.
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the peptide. The peptide and this Zn2+ ion were treated as
alternative conformations each with 50% occupancy. The
x-ray coordinates of the structures reported here have
been deposited in the protein data base (pdb) and are ac-
cessible under the pdb identifiers 4ONF (Aβ1-7 complex)
and 4ONG (Aβ1-40 complex).
Affinity determination by Biacore
Interactions between anti-Aβ antibodies and biotinylated
DAE10 peptide (Aβ1-10 conjugated to biotin at the
carboxy-terminus and immobilized to streptavidin coated
chips) were quantitatively analyzed using BIAcore plas-
mon resonance technology, and apparent kinetic rate con-
stants were derived. Bio DAE-10 peptide was diluted in
water at 1.0 mg/ml and kept at −80°C (stock). Following
immobilization of the biotinylated DAE10 peptide, varying
concentrations of each antibody were applied in triplicate
and the binding was measured as a function of time.
Affinity measurements chips were performed on chipscoated at lower densities, typically 4 to 7 response units
(RU) of the bio-peptide ligand. Antibodies were injected
in triplicate at 100 nM at a flow rate of 30 μl/minute,
injection time two minutes, post-injection time ten mi-
nutes, followed by regeneration of chips with 5 μl 0.1%
tri-fluro acetic acid (TFA). All the antibodies were run
in at least three different chips over three different
density surfaces. From these measurements the apparent
dissociation (kd) and association (ka) rate constants
were derived and used to calculate a KD value for the
interaction, corrected for active concentration of antibody.
Active concentration of antibody measurements was
carried out using chips coated with bio-DAE peptide at
high density. All the affinity data presented in this report
were analyzed using the bivalent model.
Humanization of 3D6
As the humanization of 3D6 preceded the elucidation of
its crystal structure, the variable light and heavy regions
of 3D6 were modeled using the most homologous
mouse antibodies of solved crystal structure as templates
to guide humanization of 3D6 [31-34]. The homology
model of 3D6 Fv was built using pdb identifiers 1CR9
VL and 1OPG VH, respectively, (overall VL identity =
94% and VH identity = 72%) using QUANTA (Release
dated 1999, Accelrys Software Inc., San Diego, CA,
USA). The crystal structures of the selected modeling
templates had been solved to high resolution (2 Å), and
their primary sequence fulfilled key criteria to facilitate
design of the humanized antibody based on the most
homologous human VL (Kabat accession #019230) and
VH (Kabat accession #045919) frameworks available at
the time in public databases [35]. All antibody residue
numbering in this report is according to Kabat [36], with
the one exception as noted in the figure legend.
Results
Structure of 3D6 with Aβ peptide
Crystal structures of 3D6 Fab bound to Aβ peptides were
solved to high resolution with x-ray crystallography, one
with Aβ1-7, the second with Aβ1-40. The crystallographic
data are summarized in Table 1. Due to the high degree of
similarity between the two structures, observations from
the 3D6:Aβ1-7 structure only are described in this report.
The antigen binding site of 3D6 is in a cleft positioned in
the interface between the heavy and light chain. The Aβ
peptide lies in a deep fissure arranged by the complemen-
tarity determining regions (CDRs) H1, H2, H3, L1 and L3
of the Fab (Figure 1B) and adopts a 310-helix conform-
ation where the N-terminus of the peptide is buried in the
interface between the VL and VH domains (Figures 1A
and 2). Antigen contacting antibody residues are listed in
Table 2, and illustrated in Figure 3. Aβ-Asp1 has close
contacts with both the heavy and light chains, mainly
Figure 1 Overview of the structure of 3D6 fab with Aβ1-7
peptide (pdb identifier 4ONF). A) Side view showing alpha-carbon
backbone traces of the molecules. Heavy chain is shown in cyan,
light chain in blue and Aβ peptide in yellow/orange. B) 3D6 with
Aβ1-7 view from above the molecule. Peptide is shown in stick
representation with oxygens colored red, nitrogens in blue and
carbons orange. Fab in surface representation colored white with
the exception of CDRs contacting the peptide. CDR H1 is shown
in red, H2 blue, H3 green, L1 magenta and L3 cyan. Only CDRs
contacting the peptide are colored. CDRs, complementarity
determining regions; pdb, protein data base.
Figure 2 Detailed view of Aβ 1–7 bound to 3D6. A) 3.0 sigma electron
model for phase calculations) is shown in orange. Protein and peptide are
blue, carbons in orange for the peptides, light blue for the light chain and
is shown in cyan and light chain in light blue. Aβ peptide is shown in stick
carbons in orange. In B only, peptide Asp-1 is shown. Asp-1 is buried inside
representing the surface of the peptide, is shown to illustrate the actual vo
not visible beyond the Cβ atom of His-6. C) top view. D) side view. E) side
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interacts with the light chain comprising CDR-L3. Aβ-
Glu3 mostly contacts the heavy chain CDR-H2 but also
contacts light chain CDR-L3. Aβ-Phe4 mainly interacts
with the heavy chain contacting CDR-H1, H2 and H3.
Aβ-Arg5 is in close contact to the light chain CDR-L1
and CDR-L3. Aβ-His6 does not have well-defined elec-
tron density, but it appears to contact the heavy chain
comprising CDR-H2 (Figure 3). The lack of electron
density beyond the Cβ atom in Aβ-His6 indicates that
the side chain of this residue is not bound by the anti-
body. Hence, the structure of the Fab:Aβ complex con-
firms the Aβ epitope recognized by 3D6 as previously
mapped by ELISA [16].
The structure of 3D6 with Aβ1-7 reveals excellent agree-
ment (alpha-carbon backbone root mean square deviation
of atomic position (RMSD) = 0.56 Å) with the 4HIX struc-
ture [24]. The conservation of antigen contacting antibody
residues, conformation of CDR loops, and conform-
ation of antigen recognized are detailed below (Tables 2
and 3, Figure 4). Our structure of 3D6:Aβ contrasts
with the structure of Aβ bound to gantenerumab [25],
which was reported to recognize Aβ 2–9, with weak
binding to residues 1 and 10, as well as the central epitope
by pepspot analysis of overlapping decameric peptides of
Aβ. Residues 1–11 of Aβ peptide in the gantenerumab
structure were observed bound in an extended conformation,density omit map (calculated while omitting the Aβ peptide from the
shown in stick representation with oxygens colored red, nitrogens in
cyan for the heavy chain. B, C, D, E) The surface of the heavy chain
representation with oxygens colored red, nitrogens in blue and
a deep cave on the surface of the antibody. In C, D and E a mesh,
lume of the peptide in the cave, note: the side chain of residue 6 is
view slice illustrating the depth of the cave.
Table 2 Residues of the antibody contacting Aβ (that is, within 4 angstroms) in the structure of 3D6 with Aβ1-7
Aβ residue Structure VL contacts VH contacts Peptide contacts
D1 1-7 W89 G91 R96 Y95H S100a S100b A2 E3 F4
4HIX W89 G91 R96 Y95H S100a S100b A2 E3 F4
A2 1-7 G91 T92 H93 F94 D1 E3 F4 R5 H6
4HIX G91 T92 H93 F94 D1 E3 F4 R5 H6
E3 1-7 F94 R96 W47 S50 R52 Y58 D1 A2 F4 R5
4HIX F94 R96 W47 S50 R52 Y58 D1 A2 F4 R5
F4 1-7 R96 G33 M34 S50 I51 R52 Y95 D1 A2 E3 R5
4HIX R96 G33 M34 S50 I51 R52 Y95 D1 A2 E3 R5
R5 1-7 D27d D28 Y32 G91 T92 Y95 A2 E3 F4 H6
4HIX D27d D28 Y32 G91 T92 R52 Y95 A2 E3 F4 H6
Antigen contacting antibody residues revealed by the structure of 4HIX [24] is shown for comparison. Residues are numbered according to [36].
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reversed by 180° relative to other published structures,
excluding 3D6 and 4HIX [23,26,37,38].
Several interactions between the peptide and the anti-
body involve bridging water molecules (also observed in
the 4HIX crystal structure [24]. Water molecules are
present not only on the surface of the antibody but also
inside the deep fissure at the antibody binding site, and
interact with residues from the N-terminus of the pep-
tide that are positioned at the bottom of the elongated
site. Examples are shown in Additional file 2: Figure S1.
As also noted by Miles et al. [24], a helical conformation
of Aβ has been revealed via nuclear magntic resonance
(NMR) spectroscopy [39,40]. Whereas the structure of
the amyloidogenic core of Aβ peptide has been exten-
sively characterized (see for example, [41-43]), it is well
recognized that the amino-terminus of Aβ does not
adopt a single conformation in solution. Coupled with
the solution NMR data, our results are consistent with
the notion that the amino terminus dynamically samples
a helical conformation, and it is this subpopulation of
Aβ that is recognized by 3D6. A hypothetical fit of the
NMR structure of Aβ with our structure is illustrated in
Additional file 3: Figure S2. Given the absence of elec-
tron density after residue 5 in the Aβ1-40 complex, it is
likely that upon binding the amino-terminal epitope, the
antibody can interact with different conformations
adopted by the Aβ peptide past residue 5.
Comparison of 3D6 and 12A11 binding to Aβ peptide
Both 3D6 and 12A11 recognize different but overlapping
N-terminal epitopes in the Aβ peptide, with an overlap of
three residues in the central region of the shared epitope
(Figure 5B). While 12A11 captures an extended conform-
ation of the peptide that is highly conserved among anti-
bodies binding this epitope [25,26,37,38], 3D6 binds Aβ in
a 310-helix conformation (Figure 5A). The CDR sequences
of 12A11 and 3D6 do not have high similarity, nor do theinteractions of the CDRs with the peptide. Although the
antigen-binding site in both cases is in the interface be-
tween the heavy and light chain, the antigen binding cleft
in 3D6 is very deep, where the N-terminus of the peptide
is positioned at the bottom of the fissure. In contrast, the
antigen-binding groove of 12A11 is shallow, with only the
side chains of the peptide buried in the crevice [23]. In
3D6 the peptide lies in a deep fissure as described above,
while in 12A11 the peptide adopts an extended con-
formation along the groove that is composed by CDRs
H2, H3 L1 and L3 of the Fab. Because the variation in
the binding conformation is large, and the CDRs inter-
act with different (but overlapping) epitopes in the pep-
tide (Figure 5), a direct comparison of CDR sequences is
not relevant.
Structure of 3D6 Fab:Aβ complex supports design
considerations in humanization to bapineuzumab
Humanization of 3D6 was effected by a combination of
CDR grafting of mouse residues from 3D6 VL and VH
into human frameworks, and homology model guided
retention of select mouse framework residues in the ini-
tial humanized version of the monoclonal antibody
(mAb) [31,32,35,44,45]. Superposition of the model with
the solved crystal structure of 3D6 gives an RMSD
0.74 Å for the VL domain, and 1.93 Å for VH (primarily
attributable to expected deviation in CDR-H3). The
overall RMSD for Fv is 2.35 Å, arising from a difference
in the orientation of VL and VH with respect to each
other. Two versions of humanized 3D6 were expressed
and tested (detailed below), and both versions were
demonstrated to retain all desired in vitro and in vivo
properties of the parent murine mAb [46], for example,
retention of affinity for antigen, stimulation of plaque
phagocytosis by microglia in a frozen section ex-vivo
assay, ability to recognize β-amyloid in plaque by hist-
ology of PDAPP and AD brain in frozen section, brain
localization in PDAPP and epitope specificity.
Figure 3 Interaction of Aβ residues with 3D6. For clarity, representative contacts per residue are shown. Protein and peptide are shown in
stick representation with oxygens colored red, nitrogens in blue and carbons in orange for the peptides, light blue for the light chain and cyan
for the heavy chain. Heavy chain and light chain residues are indicated by H and L prefix, respectively, Aβ peptide residues are indicated by the
prefix P. The dotted lines indicate key contacts <4 Å. Interaction of Aβ residues 1,2,3,3,4,5,6 are shown in panels A to G respectively. The overall
position of the peptide in the binding site is shown in panel H. Note: In panels G and H the side chain of residue 6 is not visible beyond the Cβ
atom of His-6. The numbering of residues in Figure 3 matches the numbering in the x-ray coordinates file (4ONF) and differs from the Kabat
numbering scheme employed in the rest of this manuscript.
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tated to human, or retained as mouse, in the two ver-
sions of humanized 3D6 are of interest. The light chain
variable region of 3D6 contains a Tyr at its amino
terminus, a rare residue at this position in human VL se-
quences. The crystal structure of 3D6 reveals that the
tyrosine residue is placed between CDRs L1 and L3. It
interacts with solvent and is mobile, evidenced by its
two very different conformations in 3D6 and 4HIX [24],illustrated in Figure 6. In 3D6 the Y1 aromatic ring is
closer to P95 of CDR-L3, whereas in 4HIX it is closer to
Q27 of CDR-L1. It should be noted that while the struc-
ture reported by Miles et al. [24] has Tyr at position 1 of
the light chain, this residue was determined to be dis-
pensable for retention of affinity in version 2 of human-
ized 3D6 (Table 4, compare h3D6v1 versus h3D6v2).
Consequently, a mutation of Y1D (the more commonly
observed residue at this position in human VL domains)
Table 3 Summary of mouse VL and VH framework residues retained in humanized 3D6/bapineuzumab based on
predicted interactions (<4 Å) with critical distal intra-chain or inter-chain residues
Mouse VL Fr residue retained
in bapineuzumab
Interacting residues revealed from
crystal structure of 3D6
Mouse VH Fr residue retained
in bapineuzumab
Interacting residue revealed
from crystal structure of 3D6
V2 Ser26:L1, Gln27:L1 A49 Ser35:H1
His93:L3, Thr97:L3 Ser50:H2, Tyr58:H2 Tyr59:H2
L36 Trp89:L3 V93 Met34:H1, Ser35:H1
Leu45(H), Trp103(H) Tyr95:H3, Ser100B:H3 Tyr102:H3
R46 Trp35(L), Leu36(L) Asp55:L2, Val58(L) R94 Tyr32:H1, Met34:H1
Tyr95:H3, Asp96:H3 Ser100B:H3,
Asp101:H3 Tyr102:H3
Ser99:H3, Ser100a:H3 Ser100b:H3, Asp101:H3
The residues were retained based on model predictions. The crystal structure of 3D6 confirmed interactions <4 Å between the retained mouse residues and the
residues listed above. CDR residues revealed in the structure of 3D6 to directly contact Aβ peptide antigen (from Table 2) are shown as boldface, italicized and
boldface font indicates CDR residue that makes an α-carbon backbone contact with the retained mouse residue. CDR residues not contacting antigen are
indicated by italics. L1, L2 and L3 indicate light chain CDR1, CDR2, and CDR3 residues respectively, and H1, H2, and H3 indicate heavy chain CDR1, CDR2 and
CDR3 residues. Framework (Fr) residues are indicated as unformatted text followed by (H) and (L) to indicate heavy or light chain origin, respectively. CDR,
complementarity determining region.
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zumab in order to minimize potential immunogenicity.
The murine VL framework residues Val2, Leu36 and
Arg46 were retained in bapineuzumab based on the
model, which predicted interactions of Val2 with residues
in CDR L1 and L3 (see Additional file 4: Figure S3). Leu36
was retained based on its predicted role for inter-chain
packing, while Arg46 was predicted to be involved in in-
teractions with H3, in addition to multiple contacts with
non-contiguous VL Fr residues. These predictions were
confirmed in the crystal structure of 3D6 as summarized
in Table 3, and detailed in Additional file 5 ‘Structural
observations in 3D6 regarding mouse VL Fr residues
retained during humanization, confirming predictions
based on homology model’.
The design of humanized 3D6 VHv1 involved replace-
ment of two rare mouse residues (Asn40, Asp42) in FR2
with the more frequent and preferred human residues at
those positions (Ala40, Gly42). Examination of theFigure 4 Conservation of Aβ and CDR loop conformation comparing
of antigen (some through water molecules which are not shown). 3D6 in p
ribbon. B) Heavy chain CDR residues within 4 Å of antigen (some through
in green, antigen from both structures in red ribbon. The dotted lines indicstructure reveals Asn40 and Asp42 are situated on a
Type I β-turn between β-strands 3 and 4 of the VH.
Asn40 forms a hydrogen bond with the main-chain ni-
trogen of Arg44, and Asp42 interacts with the Arg44
sidechain via a water molecule. Replacement of these
surface exposed rare mouse amino acids with the human
framework counterparts was considered prudent from
the perspective of eliminating potential immunogenicity
[32,47]. Interestingly, N40A and D42G mutations,
coupled with changing mouse Fr residue S41 to human
Fr residue P41, resulted in a change of conformation
from a Type I β-turn to a Type II β-turn in this region
of the molecule (Figure 7). It is not clear if this change
in conformation is attributable to the S41P alone, or the
triple mutation in combination. Nevertheless, it did not
alter the affinity (Table 4), or other activities of the hu-
manized antibody summarized below (see also [46]).
The three mouse VH framework residues retained in
humanized 3D6 VHv1 (Ala49, Val93, and Arg94) are all3D6 and humanized 3D6v1. A) Light chain CDR residues within 4 Å
urple, 4HIX structure [24] in green, antigen from both structures in red
water molecules which are not shown). 3D6 in purple, 4HIX structure
ate hydrogen bonds. CDR, complementarity determining region.
Figure 5 Comparison of 3D6 (pdb identifier 4ONF) and 12A11 (pdb identifier 3IFN) binding to Aβ. A) Superposition of the α-carbon
backbone of 3D6 and 12A11 [23] illustrating different conformations of antigen captured by antibody as revealed from the crystal structures. For
3D6, the heavy chain is shown in cyan, light chain in blue and Aβ peptide in orange; for 12A11, the heavy chain is shown in light-cyan, light
chain in light-blue and Aβ peptide in yellow. Left – top view. Right – side view. B) Primary structure from N-terminus Aβ, illustrating the epitope
recognized by 12A11 versus 3D6 in boldface. CDRs contacting antigen at each residue of the minimal epitope are indicated below the primary
structure (L-light chain CDR, H-heavy chain CDR). CDRs, complementarity determining regions; pdb, protein data base.
Figure 6 Comparison of the different conformations for Y1 at
the N-terminus of the light chain. Structure of 3D6 shown in
purple and 4HIX [24] structure shown in green. The dotted lines
indicate hydrogen bonds.
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tacts with CDR residues, contributing to preservation of
CDR conformation, and by extension, contributing to
antibody:antigen contacts (Table 3, and Additional file 5
‘Structural observations in 3D6 regarding mouse VL Fr
residues retained during humanization, confirming pre-
dictions based on homology model’).
Finally, three human VH Fr residues in v1 of humanized
3D6 were converted to germline A75S, S78T and L93V
based on the sequence of the closest human germline VH
region (V3-23), leading to version two of humanized 3D6
(bapineuzumab). The germline changes were incorporated
in bapineuzumab to minimize potential Fr changes in the
human VH (KABID 045919) arising from somatic hyper-
mutation during affinity maturation. The crystal structure
of 3D6 reveals that the methyl side chain of Ala75 is ex-
posed to solvent on a β-turn. Conversion to germline of
human Ser78 to Thr actually restores the residue at this
position in 3D6, and preserves intra-chain cross β-strand
interactions between T78 and residues on β-strand 1 of
VH. The Leu93Val germline change is a conservative mu-
tation that would preserve local interactions of the original
Fr Leu residue. These germline changes in bapineuzumab
VH were not incorporated into the molecule crystallized
by Miles et al. [24] (pdb identifier 4HIX). Version two of
humanized 3D6 was advanced for clinical development as
bapineuzumab. The integrity of the sequence of bapineu-
zumab was confirmed by mass spectroscopy, and amino
acid analysis (AAA) (data not shown, reported in the
chemistry, manufacture, and controls (CM and C) sectionof the investigative new drug (IND) application submitted
to the US Food and Drug Administration (FDA) in sup-
port of the clinical development of bapineuzumab).
While the contribution of individual light and heavy
chain framework residues described in this section to
antibody activity (particularly affinity) must await con-
firmation via systematic site directed mutation analyses
in future studies, the activity of bapineuzumab was com-
pared with 3D6 in vitro as well as in vivo in a number of
Table 4 Binding kinetics of murine, recombinant chimeric,
and two versions of humanized 3D6 to Aβ1-10 peptide
Antibody ka1 (1/Ms) kd1(1/s) KD (nM) SD n
Mu 3D6 3.61E + 05 4.12E-04 1.2 0.22 3
Chi 3D6 3.43E + 05 5.89E-04 1.8 0.73 5
Hu 3D6 v1 1.89E + 05 3.99E-04 2.1 0.07 2
Hu 3D6 v2 1.50E + 05 4.23E-04 2.8 0.54 4
"Mu" denotes Murine, "Chi" denotes chimeric, "Hu" denotes humanized.
Version two of humanized 3D6 was selected for clinical development (see
text). Specific residues in v2 of humanized 3D6 (bapineuzumab) were Y1D, V2,
L36, and R46 in VL, and N40A, D42G, A49, V93, A75S, S78T, L93V and R94 in VH,
where italicized residues denote mouse Fr residues retained during humanization.
In the table headings, ka1 denotes on rate, kd1 denotes off-rate, KD indicates
affinity, SD denotes standard deviation of KD measure, and n indicates the
number of independent replicates in the measure of affinity for each version of
the antibody tested.
Figure 7 Conformational change of a beta turn in the
alpha-carbon backbone effected by humanization of 3D6.
Ribbon depiction of the change in turn type with mutations N40A and
D42G. 3D6 in purple (type I turn) and 4HIX [24] structure in green (type
II turn) with stick representation for the mutated side-chains.
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mary criteria in antibody humanization) measurements
comparing 3D6 with bapineuzumab were carried out by
surface plasmon resonance. The data comparing 3D6
versus two versions of humanized 3D6 binding to an
Aβ1-10 peptide antigen, summarized in Table 4, revealed
that both versions of humanized 3D6 retained binding
affinity for antigen within the target 2-3X of parent
mouse antibody, although this relative difference in af-
finity measures appears insignificant when referenced to
the chimeric antibody. (See Additional file 6: Figure S4
for representative surface plasmon resonance binding
curves underlying the data in Table 4.) The conform-
ation of CDR loops, conformation of antigen binding
residues, as well as the conformation of bound antigen,
reveals excellent conservation of structure between 3D6
and 4HIX (Figure 4), supporting the design algorithm
employed in the humanization of 3D6 to bapineuzumab.
Discussion
Multiple groups have reported the structural features of
antigen recognition and antigen conformation from anti-
Aβ antibodies targeting an amino-terminal epitope of
the peptide [23-26,37,38]. The neo-epitope specificity of
3D6 combined with conformation of the bound epitope,
elucidated here at 2 Å resolution and in the structure
4HIX [24], is clearly unique among the antibodies stud-
ied to date, as well as among clinical candidates under
current investigation. Gantenerumab [25] binds Aβ in a
manner that overlaps the epitope recognized by 3D6 and
offers an interesting comparison. Although ganteneru-
mab recognizes two discontinuous epitopes on Aβ by
pepspot analysis, the crystal structure revealed binding
to Aβ residues 1–11. The reported crystal structure for
gantenerumab crystals soaked with Aβ1-11 is not pub-
licly available, limiting a detailed comparison with our
structure of 3D6 with Aβ. However, in contrast with the
310 helical conformation captured by 3D6, Aβ is de-
scribed as binding gantenerumab in an extendedconformation with antibody residues from H1, H2, H3
and L3 contributing sites of contact with antigen. This
further contrasts with our observations with antibody
3D6 CDRs, where CDRs H1, H2, H3, L1 and L3 contrib-
ute sites of contact with Aβ (Table 2). Thus, available
evidence suggests that the conformation of Aβ recog-
nized by gantenerumab is distinct from 3D6, and apart
from a reversed amino to carboxy terminal orientation,
is more similar to WO2 [38], 12A11 [23] and PFA1 [37].
Hence, the amino-terminal conformation of Aβ recog-
nized by 3D6, and most likely also bapineuzumab as evi-
denced by 4HIX, comprises a third conformation
adopted by this non-amyloidogenic and relatively un-
structured domain of the peptide.
In conjunction with the wealth of biophysical studies
of the structure of the core amyloidogenic region of
Aβ in fibrils (see for example, [41-43]), the combined
data sets from antibody crystallization studies provide a
structural snapshot of the amino-terminal conformations
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minants of AD. Based on the distinct conformations of
Aβ recognized by 3D6 (helical) versus 12A11, gantener-
umab, WO2, PFA1 (extended), it is reasonable to specu-
late that 12A11 and 3D6 target different amino-terminal
conformations of Aβ peptide presented in its multiple
states. Consequently, one could envision a scenario
whereby antibody binding to the amino terminal epitope
of Aβ alone could skew the equilibrium distribution of
total Aβ species (soluble monomer to amyloid plaque
deposited forms) toward the antibody bound state, and
thereby potentially affect the overall steady-state distri-
bution of the different forms in which Aβ may exist at
any given point in time.
Although the structure of 3D6:Aβ reported here is in
very close agreement with its humanized version 4HIX
[24], the discrepancy between our reports in the affinity
of humanized 3D6 v1 (equivalent to 4HIX) merits com-
ment. We observed low nanomolar affinity for Aβ with
both versions of humanized 3D6 and a 2-3X loss of af-
finity between murine or chimeric 3D6 and humanized
(Table 4). Miles et al. reported an affinity of 76 nM for
Aβ1-40, 150 nM for Aβ1-28, and low μM for Aβ1-7,
from their synthetic Fab of humanized 3D6 (equivalent
to our version 1). These values reflected a 15 to 30 fold
loss of affinity in the humanized mAb when compared
to a 5 nM affinity of 3D6 for Aβ1-40 reported by
DeMattos et al. [48]. Our measure of the affinity of 3D6
for Aβ1-10 is in closer agreement with that reported by
DeMattos et al. The discrepancy between affinity mea-
surements reported here (and by DeMattos et al.), ver-
sus the affinity reported by Miles et al. can be attributed
primarily to the use of whole antibody (this report and
DeMattos et al.) versus Fab (Miles et al.). A secondary
contributor to our discrepant affinity measures may be
attributable to differences in methodology for affinity de-
termination (surface plasmon resonance in our report
and microscale thermophoresis by Miles et al. [24]). The
structural details for antigen recognition by antibody
provide insight toward modulating affinity via site di-
rected mutagenesis.
Antibody humanization provided the first approach to
solving the limiting immunogenicity of mouse antibodies
in man [32,44,47,49-51]. Antibody engineering technology
has been continuously evolving over that time period,
from pioneering work with phage display [52-56] and
xeno-mouse based approaches [57-59] to more esoteric
recombinant engineering of xenogenic species derived
antibodies and yeast display based approaches (for re-
views, see [60-62]). The excellent agreement we report
between the structures of 3D6:Aβ and that of 4HIX,
as summarized in Table 2 and Figure 4, attests to the ro-
bustness and continued viability of antibody humanization
as a rapid and efficient technology for lead optimization ofbiological drug candidates. The approaching expiry of
the exclusivity period of archetypal humanization pat-
ents [63-66] provides an illustrative (but not compre-
hensive) rationale for the continued value of antibody
humanization as an economical platform for drug de-
velopment going forward.
A bi-specific [67,68] or dual variable domain [69] anti-
body combining recognition of the two conformations of
Aβ revealed from crystal structure studies, that is, ex-
tended conformation on one arm and helical conform-
ation on the other arm, would offer intriguing dual
activity that could be particularly well suited for disag-
gregation of β-amyloid plaque independent of effector
cell engagement. Recent progress with immunotherapy
targeting Tau in preclinical models is revealing preferred
targets for antibody binding [70]. Structural investigation
of the conformation of tau recognized by efficacious
anti-Tau antibodies will be informative regarding the
mechanisms underlying intercellular transmission of
these pathological entities, and furthermore, enable de-
sign of bi-specific antibodies capable of recognizing and
neutralizing both tau and Aβ.
Conclusions
Disease modifying therapy of AD remains a significant
unmet medical need [71-74]. The disease modifying ef-
fects of Aβ-targeted immunotherapy [4] have been
widely reproduced in preclinical models. Although the
initial clinical trials with bapineuzumab failed to achieve
the clinical end-points at the disease stage tested [11],
the continued refinement of Aβ targeted immunother-
apy for AD has resulted in numerous follow-on passive
and active immunotherapy approaches currently under-
going clinical investigation. The efforts underway target
either different epitopes of Aβ, (for example, Solaneuzu-
mab [75] and Gantenerumab [15]), different species of
Aβ (for example, oligomer specific antibodies discovered
via a range of technologies [76-78] versus plaque specific
[48]), or engage different mechanisms to effect clearance
or neutralization of Aβ mediated pathologies, for ex-
ample, effector function (Crenezumab [12] versus bapi-
neuzumab [3] and gantenerumab [15]). The report by
Lu et al. demonstrating conformational variation of
β-amyloid fibril structure in AD patients [79] suggests
utility as well as limitations of approaches targeting a
specific conformation. As we have reported, 3D6 shows
the ability to target and neutralize multiple species of Aβ
[5], in an Fc receptor dependent as well as independent
manner. Current evidence based on pre-clinical studies
suggests that attenuated effector activity may be prefera-
ble in an immunotherapeutic targeting Aβ [20]. Hence, a
second generation anti-Aβ therapeutic with attenuated ef-
fector function, as embodied in crenezumab and AAB-003
(containing humanized 3D6 variable regions), or a bi-
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conformations, or both Aβ and Tau (as discussed earlier),
which targets all forms of pathogen to neutralize, or pro-
mote, its clearance, may prove to be efficacious when ap-
plied in a disease stage appropriate manner [71,74].Additional files
Additional file 1: Table S1. Crystallization conditions. Conditions for
crystallization of 3D6 Fab with Aβ1-6 peptide, and Aβ1-40 peptide, are
listed.
Additional file 2: Figure S1. A pdf file. Some examples for 3D6 water
mediated interaction with Aβ1-7. Protein and peptide are shown in stick
representation with oxygens colored red, nitrogens in blue and carbons
in orange for the peptides, light blue for the light chain and cyan for the
heavy chain. The dotted lines indicate key contacts <4 Å.
Additional file 3: Figure S2. A pdf file. Model for Aβ binding by 3D6.
The model for the peptide was prepared by: 1. Superpositioning residues
1–5 of the NMR structure of Aβ1-28, pdb id 1AMB (first structure in the
NMR pdb file) on 1–5 of 3D6. 2. Superpositioning of the longer Aβ1-42
NMR structure (the first structure in the pdb file, pdb id 1IYT) on 1AMB
(residues 18–25) The final model for the peptide contains: residues 1–5
from the peptide bound in the 3D6 + Aβ1-7 peptide structure (A),
residues 6–26 from 1AMB [40] (B) and residues 27–42 from 1IYT [39]
(C). The final model was regularized in the section where two models
connect (±2 residues, residues 3–7 and 24–28) to bring the bonds in the
connection to a reasonable range (D). In the final model (E, F) some
clashes are observed in the region of H-Arg-52 and H-Arg-57, residues
that are part of CDR-H2, and peptide residue Aβ-Asp7. A possible
resolution for the observed clashes could be envisioned if the loop
comprising CDR-H2, which contains many Gly residues, were to adopt a
slightly different conformation. Alternately, if the rotamers for H-Arg-52,
H-Arg-57, H-Tyr-59 and Aβ-Asp-7 were to be different, the modeled
protein would be able to accommodate the conformation of the peptide
illustrated and overcome the clashes.
Additional file 4: Figure S3. A pdf file. Interaction of framework
residue with CDRs. VL residue V2 (thick purple stick in center) which was
retained in bapineuzumab based on predicted interaction with residues
in CDR-L1 and L3. L1 shown in dark blue and L3 in light blue. Hydrogen
bonds are shown as dotted lines.
Additional file 5: ‘Structural observations in 3D6 regarding mouse
VL Fr residues retained during humanization, confirming
predictions based on homology model.’
Additional file 6: Figure S4. A pdf file. Surface plasmon resonance
binding profiles of murine-3D6 IgG2b (red), chimeric-3D6 IgG1 (blue) and
humanized-3D6 v2 (green) are shown on 5.0 RU of biotinylated-Aβ1-10
peptide immobilized on streptavidin coated chip.Abbreviations
3D6Aβ1-40: Fab 3D6 + Aβ residues 1–40; 3D6Aβ1-7: Fab 3D6 + Aβ residues
1–7; AAA: amino acid analysis; AD: Alzheimer’s disease; APP: amyloid
precursor protein; Aβ: amyloid beta peptide; BACE: beta-site APP cleavage
enzyme; CDR: complementarity determining region; CM and C: chemistry,
manufacture, and controls; ELISA: enzyme linked immunosorbent assay;
Fab: fragment antigen binding, comprising variable and first constant
regions of heavy and light chains of an antibody; Fc: fragment constant, that
is, constant region of antibody comprising the hinge, second and third
constant regions of immunoglobulin heavy chain; Fr: framework;
Fv: fragment variable, that is, just the VL and VH fragments of an antibody;
H1: CDR1 in VH; H2: CDR2 in VH; H3: CDR3 in VH; IND: investigative new
drug; L1: CDR1 in VL; L2: CDR2 in VL; L3: CDR3 in VL; PDAPP: PDGF promoter
driven APP transgenic mouse model of AD; pdb: protein data base;
PDGF: platelet-derived growth factor; RMSD: root mean square deviation of
atomic position; TLS: Translation Libration Screw; v: version; VH: variable
region, heavy chain; VL: variable region, light chain.Competing interests
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